Why the study?
Rapid and robust analytical methods to quantify Coxsackievirus A21 total, empty, and full virus particles are needed to support process development, meet regulatory requirements, and validate manufacturing processes.
Answers are grounded in this paper and cite their sources.
An automated capillary Western blot assay was developed to rapidly and robustly quantify Coxsackievirus A21 viral proteins and particle ratios, supporting manufacturing process optimization.
A prototype strain of Coxsackievirus A21 (CVA21) is being evaluated as an oncolytic virus immunotherapy. CVA21 preferentially lyses cells that upregulate the expression of intercellular adhesion molecule 1, which includes some types of tumor cells. CVA21 has an icosahedral capsid structure made up of 60 protein subunits encapsidating a viral RNA genome with a particle diameter size of 30 nm. Rapid and robust analytical methods to quantify CVA21 total, empty, and full virus particles are important to support the process development, meet regulatory requirements, and validate manufacturing processes. In this study, we demonstrate the detection of all four CVA21 capsid proteins, VP1, VP2, VP3, and VP4, as well as VP0, a surrogate for empty particles, using in-house-generated antibodies. An automated and quantitative capillary Western blot assay, Simple Western, was developed using these antibodies to quantify CVA21 total particles through VP1, empty particles through VP0, relative ratio of empty to full particles through VP0 and VP4, and the absolute ratio of empty to total particles through VP0 and VP1. Finally, this Simple Western method was used to support CVA21 cell culture and purification process optimization as a high-throughput analytical tool to make rapid process decisions.
No takes yet. Share an insight, caveat, or question.
Gillespie et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: